TissueCypher Barrett's Esophagus Assay Technology Identifies Potential Esophageal Cancer
Clinicopathologic risk factors like age, sex, obesity, family history, and expert pathology have been shown to have limited ability to predict progression to esophageal cancer. TissueCypher outperforms these risk factors and provides physicians with an actionable risk score and the patient's personalized 5-year risk of progression.
TissueCypher® Spatialomics – Demonstrates platform power to deliver clinically actionable results.
Learn more about TissueCypher by visiting our website at www.TissueCypher.com.
Видео TissueCypher Barrett's Esophagus Assay Technology Identifies Potential Esophageal Cancer канала Castle Biosciences
TissueCypher® Spatialomics – Demonstrates platform power to deliver clinically actionable results.
Learn more about TissueCypher by visiting our website at www.TissueCypher.com.
Видео TissueCypher Barrett's Esophagus Assay Technology Identifies Potential Esophageal Cancer канала Castle Biosciences
Комментарии отсутствуют
Информация о видео
20 февраля 2023 г. 3:03:20
00:03:59
Другие видео канала
Teddi Mellencamp and Dr. Aaron Farberg discuss the importance of advocating for yourself
Melanoma and the Role of Personalized Medicine: A Dermatologist/Dermatopathologist’s Perspective
The Impact of MyPath Testing: Dr. Carlos Gomez-Meade on Patient Care and Reassurance
The Power of Gene Expression Profile Testing in Cancer Care
Dr. Goldberg - Diagnostic & Prognostic Testing in Melanoma and Cutaneous Squamous Cell Carcinoma
Hear about the patient experience when it comes to the cost of DecisionDx-Melanoma
Dr. Goldberg - Comprehensive Diagnostic Offering
Atypical Skin Lesion in 54-Year-Old: How MyPath Melanoma Guided Surgical Decision | Dr. Brent Moody
Don't let fear define your journey: a uveal melanoma patient journey
The DecisionDx®-Melanoma Test Complements Current Melanoma Staging
The Limitations of Traditional Approaches
![[Webinar] Pooled Analysis Using TissueCypher to Predict Progression in Barrett's Esophagus](https://i.ytimg.com/vi/rnveD331MyM/default.jpg)
[Webinar] Pooled Analysis Using TissueCypher to Predict Progression in Barrett's Esophagus
How DecisionDx-Melanoma Predicts Tumor Behavior: How a Dermatologist Explains the Test to Patients
When to Use MyPath Melanoma: Dr. Shannon Trotter on Diagnosing Ambiguous Skin Lesions
![[Webinar / EndoscopyNow] Establishing Individual Patient Risk for Progression to Esophageal Cancer](https://i.ytimg.com/vi/a_F1p9HK2MA/default.jpg)
[Webinar / EndoscopyNow] Establishing Individual Patient Risk for Progression to Esophageal Cancer
Highlights from DDW2024: A Discussion on Improving Management of Non-Dysplastic Barrett’s Esophagus
How MyPath Melanoma Test Helps Avoid Large Surgeries:
Dr. Caitlin Houghton shares her thoughts on why treating Barrett’s esophagus can be difficult
Kristen Oelschlager, Castle Biosciences' COO and 2024 Arizona Bioscience Leader of the Year
AI Unlocks the Clinical Utility of Spatialomics — Matthew Goldberg PMWC 2025
